Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing the recent FDA accelerated approval for Jaypirca from Eli Lilly for treating CLL/SLL in patients that received at least two prior lines of therapy based on the study BRUIN

Ticker(s): LLY

Who's the expert?

Institution: Cancer Care Centers of South Texas
Hematologist/Oncologist at Cancer Care Centers of South Texas and Clinical Associate Professor in Medicine at the University of Texas Health Science Center at San Antonio.
Currently treats 10-12 patients with Follicular lymphoma and/or refractory B-cell non-Hodgkin lymphoma
Specializing in the management of all adult solid tumors, lymphomas and leukemias.

Interview Goal

This interview will focus on the recent FDA accelerated approval for Jaypirca from Eli Lilly for treating chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) in patients that received at least two prior lines of therapy based on the study BRUIN

Do you want answers to these questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.